Dapivirine

Dapivirine.svg

Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the prevention of HIV/AIDS. It is primarily administered through a vaginal ring, which is designed to provide sustained release of the drug over a period of time.

Mechanism of Action

Dapivirine works by inhibiting the activity of the reverse transcriptase enzyme, which is essential for the replication of HIV. By blocking this enzyme, dapivirine prevents the virus from multiplying and spreading within the body.

Development and Approval

Dapivirine was developed by the International Partnership for Microbicides (IPM). The dapivirine vaginal ring has undergone extensive clinical trials to evaluate its safety and efficacy. In 2020, the European Medicines Agency (EMA) gave a positive opinion on the dapivirine vaginal ring, and it has been approved for use in several countries.

Clinical Trials

Several clinical trials have been conducted to assess the effectiveness of dapivirine in preventing HIV infection. Notable among these are the ASPIRE and The Ring Study trials, which demonstrated a significant reduction in the risk of HIV infection among women who used the dapivirine vaginal ring.

Usage

The dapivirine vaginal ring is inserted into the vagina and left in place for a month, after which it is replaced with a new ring. This method of delivery ensures a steady release of the drug, maintaining effective drug levels in the vaginal tissues.

Side Effects

Common side effects of dapivirine include mild to moderate vaginal irritation, discomfort, and discharge. Serious side effects are rare but can include allergic reactions.

Advantages

The dapivirine vaginal ring offers several advantages over other forms of HIV prevention, such as oral pre-exposure prophylaxis (PrEP). These include:

• Long-acting protection
• Reduced need for daily adherence
• Discreet use

Future Directions

Research is ongoing to explore the potential of dapivirine in other forms of delivery, such as injectable formulations and topical gels. Additionally, studies are being conducted to evaluate its effectiveness in different populations, including adolescents and pregnant women.

See Also

• HIV/AIDS
• Non-nucleoside reverse transcriptase inhibitor
• Pre-exposure prophylaxis
• International Partnership for Microbicides

External Links

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian